Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 293, Issue 1, 2000, Pages 136-150

  Smith, Sidney R ^a   Terminelli, Carol ^a   Denhardt, Georgetta ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; INTERLEUKIN 10; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG RECEPTOR BINDING; ENDOTOXEMIA; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES;

ANIMALS; BORNANES; CANNABINOIDS; CYTOKINES; ENDOTOXEMIA; ENDOTOXINS; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-2; LIGANDS; LIPOPOLYSACCHARIDES; MALE; MICE; MORPHOLINES; NAPHTHALENES; PIPERIDINES; PROPIONIBACTERIUM ACNES; PYRAZOLES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TETRAHYDROCANNABINOL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034069673     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Berdyshev E, Boichot E, Corbel M, Germain N and Lagente V (1998) Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Pharmacol Lett 63:125-129.
2. Dewey WL (1986) Cannabinoid pharmacology. Phrarmacol Rev 38:151-178.
3. Derocq J-M, Segiu M, Marchand J and Le Fur G (1995) Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett 369:177-182.
4. Carayon P, Marchand J, Dussossoy D, Derocq J-M, Jbilo O, Bord A, Bouaboula M, Galiegue S, Mondiere P, Penarier G, Le Fur G, Defrance C and Casellas P (1998) Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood 92:3605-3615.
5. Compton DR, Aceto MD, Lowe J and Martin BR (1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A). Inhibition of delta 9-tetrahydrocannabinol-induced responses and agonist activity. J Pharmacol Exp Ther 277:586-594.
6. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma A and Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-450.
7. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G and Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61.
8. Gallily R, Yamin A, Waksmann Y, Ovadia H, Weidenfeld J, Bar-Joseph A, Biegon A, Mechoulam R and Shohami E (1997) Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by Dexanabinol (HU-211), a nonpsychotropic cannabinoid. J Pharmacol Exp Ther 283:918-924.
9. Haley TJ and McCormick WG (1957) Pharmacological effects produced by intrace-rebral injection of drugs in the conscious mouse. Br J Pharmacol 12:12-15.
10. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, DeCosta BR and Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936.
11. Johnson MR and Melvin LS (1986) The discovery of nonclassical cannabinoid analgetics, in Cannabinoids as Therapeutic Agents (Mechovlam Red) pp 121-145, CRC Press, Boca Raton, FL.
12. 9-tetrahydrocannabinol cytokines and immunity to Legionella pneumophilia. Proc Soc Exp Biol Med 209:205-212.
13. Lake KD, Martin BR, Kunos G and Vara K (1997) Cardiovascular effects of annadamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 29:1204-1210.
14. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R and Ward SJ (1991) Behavioral, biochemical and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40:471-478
15. Pacheo MA, Childers SR, Arnold R, Casiano F and Ward SJ (1991) Aminoalkylindoles: Actions on specific G-protein-linked receptors. Pharmacol Exp Ther 257: 170-183.
16. Pertwee RG and Fernando SR (1996) Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br J Pharmacol 118:2053-2058.
17. Pertwee RG, Fernando SR, Nash JE and Coutts AA (1996) Further evidence of cannabinoid CB1 receptors in guinea-pig small intestine. Br J Pharmacol 118: 2199-2205.
18. Reche I, Fuentes JA and Ruiz-Gayo M (1996) A role for central cannabinoid and opiod systems in peripheral delta 9-tetrahydrocannabinol-induced analgesia in mice. Eur J Pharmacol 301:75-81.
19. Richardson JD, Aanonsen L and Hargreaves KM (1997) SR141716A, a cannabinoid receptor antagonist produces hyperalgesia in untreated mice. Eur J Pharmacol 319:R3-R4.
20. Richardson JD, Kilo S and Hargreaves KM (1998), Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75:111-119.
21. Rinaldi-Carmona M, Barth F, Heaulme, M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliar G, Caput D, Ferrara P, Soubrie P, Breliere J-C and Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
22. Rinaldi-Carmona M, Barth F, Heaulme M, Alonso R, Shire D, Calandra B, Congy C, Soubrie P, Breliere J-C and LeFur G (1995) Biochemical and pharmacological characterization of SR141716A, the first potent and selective cannabinoid receptor antagonist. Life Sci 56:1941-1947.
23. Rinaldi-Carmona M, Barth F., Millan J, Derocq J-M, Casellas P Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Porttier M, Shire D, Breliere J-C and Le Fur G (1998) SR1442528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-650.
24. Smith SR, Calzetta A, Bankowski J, Kenworthy-Bott L and Terminelli C (1993) Lipopolysaccharide-induced cytokine and mortality in mice treated with Corynebacterium parvum. J Leukoc Biol 54:23-29.
25. Smith SR, Terminelli C, Denhardt G, Narula S and Thorbecke GJ (1996) Administration of interleukin-10 at the time of priming protects Corynebacterium parvum-primed mice against LPS- and TNF-α-induced lethality. Cell Immunol 173:207-214.
26. Varga K, Lake KD, Martin BR and Kunos G (1995) Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anadamide. Eur J Pharmacol 278:279-283.
27. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR and Kunos G (1997) Activation of peripheral cannabinoid receptors in haemorrhagic shock. Nature (Lond) 390:518-521.